Busadre, Joy D.

HRN: 01-18-25  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/23/2023
CEFTAZIDIME 1GM (VIAL)
11/23/2023
11/29/2023
IV
1 Gram
Q 8 Hours
Carcinoma Breast
Waiting Final Action 
11/23/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
11/23/2023
11/29/2023
IV
300mg
Q6h
Invasive CA Breast, Left
Waiting Final Action 
12/03/2023
CLINDAMYCIN 300MG (CAP)
12/03/2023
12/10/2023
PO
300mg
TID
Invasive Breat Ca, Left, Infected
Waiting Final Action 
12/05/2023
CLINDAMYCIN 300MG (CAP)
12/05/2023
12/11/2023
PO
300mg
Tid
Infected Breast Mass Left
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: